CompletedPhase 3NCT02172950
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Studying Severe hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Program DirectorCSL Behring
- Intervention
- rVIII-SingleChain(biological)
- Enrollment
- 246 target
- Eligibility
- MALE
- Timeline
- 2014 – 2021
Study locations (30)
- Study Site 8400213, San Diego, California, United States
- Study Site 8400241, Aurora, Colorado, United States
- Study Site 8400118, Hartford, Connecticut, United States
- Study Site 8400116, Miami, Florida, United States
- Study Site 8400184, Chicago, Illinois, United States
- Study Site 8400204, New Orleans, Louisiana, United States
- Study Site 8400240, Dallas, Texas, United States
- Study Site 8400041, Houston, Texas, United States
- Study Site 8400154, Milwaukee, Wisconsin, United States
- Study Site 0360014, Melbourne, Australia
- Study Site 0360028, Nedlands, Australia
- Study Site 0360031, Perth, Australia
- Study Site 0400012, Graz, Austria
- Study Site 0400003, Linz, Austria
- Study Site 0400001, Vienna, Austria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02172950 on ClinicalTrials.govOther trials for Severe hemophilia A
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06816953Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII ProphylaxisChulalongkorn University
- RECRUITINGPHASE3NCT06142552Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinJiangsu Gensciences lnc.
- ACTIVE NOT RECRUITINGPHASE3NCT06224907Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia ABioMarin Pharmaceutical
- RECRUITINGNCT05981274A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)Tri-Service General Hospital
- ENROLLING BY INVITATIONNCT05768386A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)BioMarin Pharmaceutical
- RECRUITINGPHASE4NCT04690322POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesUniversity of Texas Southwestern Medical Center